May 2004
Volume 45, Issue 13
ARVO Annual Meeting Abstract  |   May 2004
Reduced collateral effect of photodynamic therapy (PDT) using a newwater–soluble photosensitizer agent
Author Affiliations & Notes
  • F. Valamanesh
    Lito, Fondation A de Rothschild, Paris, France
  • M. Berdugo
    INSERM U450, Paris, France
  • R.A. Bejjani
    Hotel–Dieu Hospital
  • M. Savoldelli
    Hotel–Dieu Hospital
  • J.–C. Jeanny
    INSERM U450, Paris, France
  • P.–H. Brun
    Steba Biotech, Toussus le Noble, France
  • D. Blanc
    Steba Biotech, Toussus le Noble, France
  • D. BenEzra
    Haddasah Hebrew University Hospital
  • F. Behar–Cohen
    Fondation A de Rothschild
  • Footnotes
    Commercial Relationships  F. Valamanesh, None; M. Berdugo, None; R.A. Bejjani, None; M. Savoldelli, None; J. Jeanny, None; P. Brun, Steba Biotech E; D. Blanc, Steba Biotech E; D. BenEzra, None; F. Behar–Cohen, None.
  • Footnotes
    Support  Steba Biotech
Investigative Ophthalmology & Visual Science May 2004, Vol.45, 3188. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      F. Valamanesh, M. Berdugo, R.A. Bejjani, M. Savoldelli, J.–C. Jeanny, P.–H. Brun, D. Blanc, D. BenEzra, F. Behar–Cohen; Reduced collateral effect of photodynamic therapy (PDT) using a newwater–soluble photosensitizer agent . Invest. Ophthalmol. Vis. Sci. 2004;45(13):3188.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Abstract: : Purpose: To evaluate the photodynamic treatment (PDT) potential of a new hydrosoluble photosensitizer (WST11, Negma). Methods: 136 pigmented rabbits were used. WST11 and verteporfin PDT effects were investigated for occlusive and non–occlusive parameters. Treated rabbit eyes were followed by indirect ophthalmoscopy, fluorescein angiography (FA) and histology at various intervals after PDT. Results: WST11 PDT using a fluence of 50J/cm2, 5mg/kg drug dose and DLI of 1 minute induced total choroidal occlusion associated with structural lesions of the overlying RPE and retina in 100% of the treated eyes. Weaker, non–occlusive PDT parameters (25J/cm2, 5mg/kg and DLI 10 minutes) did not induce choriocapillaries occlusion nor retinal lesions. Verteporfin PDT using 12mg/m2 drug dose, fluence 100 J/cm2 and DLI 5 minutes induced occlusive events in 89% of the eyes and histology damage of the overlying retina and RPE layer. Weaker non–occlusive verteporfin PDT parameters did not induce any choriocapillaries occlusion on FA. However in these eyes, definite structural damage of the retina and choroid tissues were observed on histology. Similar to verteporfin, WST11 PDT induces transient occlusion of the choriocapillaries observed up to one week after treatment. WST11 PDT parameters not inducing vessel occlusion do not cause RPE or retina structural damage. Conclusions: Despite its capacity to induce vessel obstruction, WST11 PDT does not cause damage to the RPE and overlying retina when no occlusion of the choriocapillaries takes place. The possibility to use WST11 PDT for the treatment of CNV in age–related macular degeneration remains to be further investigated.

Keywords: photodynamic therapy • drug toxicity/drug effects • choroid 

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.